Jul 29, 2025 | peptide blends
CJC-1295 and Growth hormone–releasing peptide–2 (GHRP-2) represent two distinct but potentially complementary strategies for increasing growth hormone (GH) output in laboratory settings. GHRP‑2 is a small, synthetic hexapeptide originally engineered from modifications...
Jul 22, 2025 | peptide blends
In recent years, researcher-driven investigations in laboratory settings have explored the potential of BPC-157 and TB-500 blend. These are two synthetic peptides that may support fundamental repair-related processes in different cells and tissues. According to...
May 16, 2025 | peptide blends
Frag 176-191, Mod GRF 1-29, and Ipamorelin are peptides that researchers believe may impact the metabolism of fat cells through several different mechanisms. For example, Fragment 176-191 is typically characterized as a synthetic peptide derived from the C-terminal...
Mar 27, 2025 | peptide blends
Modified Growth Hormone Releasing Factor (Mod GRF (1-29)) and Growth Hormone Releasing Peptide-6 (GHRP-6) are research peptides that may interact with different receptors on pituitary cells and possibly trigger the production of growth hormone (hGH). It is thought...
Dec 10, 2024 | peptide blends
Mod GRF 1-29 (also referred to as CJC-1295 without DAC) and Ipamorelin are both synthetic peptides that have attracted scientific interest primarily because they have the potential to influence the growth hormone release mechanisms of pituitary gland cells under...
Nov 21, 2024 | peptide blends
The Modified GRF 1-29 and GHRP-2 peptide blend consists of two synthetic peptides engineered to possibly stimulate growth hormone synthesis and regulation, mirroring some functions of endogenously occurring peptides. Modified GRF 1-29, also referred to as CJC-1295...
